VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update
09 août 2019 08h00 HE
|
VBI Vaccines, Inc.
Positive top-line data from PROTECT Phase 3 for Sci-B-Vac®, trivalent hepatitis B vaccine, announced June 2019 – top-line data from second Phase 3 study, CONSTANT, expected around year-end 2019ASCO...